DiaMedica Therapeutics (DMAC) Earnings Date, Estimates & Call Transcripts $5.15 +0.55 (+11.96%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$5.30 +0.15 (+2.82%) As of 07/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DiaMedica Therapeutics Earnings Summary DiaMedica Therapeutics issued Q1 2025 earnings on May 13, 2025, reporting an EPS of -$0.18, which hit the consensus estimate of -$0.18. With a trailing EPS of -$0.64, DiaMedica Therapeutics' earnings are expected to decrease next year, from ($0.59) to ($0.80) per share. Upcoming Q2 Earnings DateAug. 6After Market ClosesEstimatedConsensus EPS (May. 13) -$0.18 Actual EPS (May. 13) -$0.18 Q1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)DMAC Upcoming EarningsDiaMedica Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get DiaMedica Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaMedica Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataDMAC Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. DiaMedica Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.18-$0.18-$0.18Q2 20251-$0.18-$0.18-$0.18Q3 20251-$0.18-$0.18-$0.18Q4 20251-$0.18-$0.18-$0.18 DiaMedica Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/6/2025(Estimated)--------5/13/2025Q1 2025-$0.18-$0.18--$0.18--3/17/2025Q4 2024-$0.17-$0.18 -$0.01-$0.18--8/7/2024Q2 2024-$0.16-$0.13+$0.03-$0.13--5/8/2024Q1 2024-$0.16-$0.14+$0.02-$0.14--3/20/2024--$0.14-$0.14--$0.14--11/13/2023Q3 2023-$0.14-$0.12+$0.02-$0.12--8/14/2023Q2 2023-$0.22-$0.16+$0.06-$0.16-- DiaMedica Therapeutics Earnings - Frequently Asked Questions When is DiaMedica Therapeutics' earnings date? DiaMedica Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, August 6th, 2025 based off last year's report dates. Learn more on DMAC's earnings history. Did DiaMedica Therapeutics beat their earnings estimates last quarter? In the previous quarter, DiaMedica Therapeutics (NASDAQ:DMAC) reported ($0.18) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.18). Learn more on analysts' earnings estimate vs. DMAC's actual earnings. How can I listen to DiaMedica Therapeutics' earnings conference call? The conference call for DiaMedica Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read DiaMedica Therapeutics' conference call transcript? The conference call transcript for DiaMedica Therapeutics' latest earnings report can be read online. Read Transcript How much profit does DiaMedica Therapeutics generate each year? DiaMedica Therapeutics (NASDAQ:DMAC) has a recorded net income of -$24.44 million. DMAC has generated -$0.64 earnings per share over the last four quarters. What is DiaMedica Therapeutics' EPS forecast for next year? DiaMedica Therapeutics' earnings are expected to decrease from ($0.59) per share to ($0.80) per share in the next year. More Earnings Resources from MarketBeat Related Companies Maravai LifeSciences Earnings Date Iovance Biotherapeutics Earnings Date Urogen Pharma Earnings Date Tilray Brands Earnings Date Tango Therapeutics Earnings Date Stoke Therapeutics Earnings Date Prime Medicine Earnings Date Dianthus Therapeutics Earnings Date Phathom Pharmaceuticals Earnings Date Upstream Bio Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Amazon Stock Rally Hits New Highs: Buy Into Earnings?TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft Earnings This page (NASDAQ:DMAC) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
